Cogent Biosciences Advances Bezuclastinib NDA Submission Under FDA's RTOR Program
Event summary
- Cogent Biosciences to initiate NDA submission for bezuclastinib in combination with sunitinib for GIST patients under FDA's RTOR program.
- PEAK trial demonstrated a median progression-free survival (mPFS) of 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy.
- Overall response rate (ORR) of 46% achieved with bezuclastinib combination compared to 26% with sunitinib.
- NDA submission completion expected in April 2026, with full PEAK trial results to be presented at a major medical meeting in the first half of 2026.
The big picture
Cogent Biosciences' NDA submission for bezuclastinib marks a significant step in addressing the unmet need for GIST patients resistant to imatinib. The FDA's RTOR program aims to expedite the review process, potentially bringing a new treatment option to market sooner. The positive PEAK trial results position bezuclastinib as a potential first new approval in this patient population in over 20 years, highlighting the strategic importance of this development in the precision oncology space.
What we're watching
- Regulatory Approval
- The pace at which the FDA completes the RTOR review process and approves bezuclastinib will determine its commercialization timeline.
- Clinical Validation
- Whether the full PEAK trial results, to be presented in the first half of 2026, will further solidify bezuclastinib's clinical benefit and support its market positioning.
- Market Expansion
- How Cogent Biosciences plans to leverage the bezuclastinib combination for first-line GIST patients, potentially expanding its addressable market.
Related topics